NO20082203L - Fremgangsmater for a behandle sentralnervesystemforstyrrelser med en lavdosekombinasjon av escitalopram og bupropion - Google Patents

Fremgangsmater for a behandle sentralnervesystemforstyrrelser med en lavdosekombinasjon av escitalopram og bupropion

Info

Publication number
NO20082203L
NO20082203L NO20082203A NO20082203A NO20082203L NO 20082203 L NO20082203 L NO 20082203L NO 20082203 A NO20082203 A NO 20082203A NO 20082203 A NO20082203 A NO 20082203A NO 20082203 L NO20082203 L NO 20082203L
Authority
NO
Norway
Prior art keywords
escitalopram
bupropion
nervous system
central nervous
disorder
Prior art date
Application number
NO20082203A
Other languages
English (en)
Inventor
Jeffrey Jonas
Anjana Bose
Joyce Tsai
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of NO20082203L publication Critical patent/NO20082203L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Reproductive Health (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Foreliggende oppfinnelse vedrører en fremgangsmåte for behandling av en lidelse i sentralnervesystemet, slik som sinnslidelser (f.eks. alvorlig depressiv lidelse) eller en angstlidelse (f.eks. generell angstlidelse, sosial angstlidelse, posttraumatisk stresslidelse og panikklidelse) med en lavdosekombinasjon av escitalopram og bupropion.
NO20082203A 2005-10-14 2008-05-14 Fremgangsmater for a behandle sentralnervesystemforstyrrelser med en lavdosekombinasjon av escitalopram og bupropion NO20082203L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US72727605P 2005-10-14 2005-10-14
US81088206P 2006-06-02 2006-06-02
US80408606P 2006-06-06 2006-06-06
PCT/US2006/060006 WO2007053796A2 (en) 2005-10-14 2006-10-16 Methods of treating central nervous system disorders with a low dose combination of escitalopram and bupropion

Publications (1)

Publication Number Publication Date
NO20082203L true NO20082203L (no) 2008-07-09

Family

ID=38006532

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20082203A NO20082203L (no) 2005-10-14 2008-05-14 Fremgangsmater for a behandle sentralnervesystemforstyrrelser med en lavdosekombinasjon av escitalopram og bupropion

Country Status (11)

Country Link
US (2) US7569605B2 (no)
EP (1) EP1954257A4 (no)
JP (1) JP2009511606A (no)
KR (1) KR20080080094A (no)
AU (1) AU2006308635A1 (no)
BR (1) BRPI0617382A2 (no)
CA (1) CA2625835A1 (no)
EA (1) EA200801081A1 (no)
IL (1) IL190831A0 (no)
NO (1) NO20082203L (no)
WO (1) WO2007053796A2 (no)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ561375A (en) 2005-06-27 2011-06-30 Biovail Lab Int Srl Bupropion hydrobromide, and crystalline forms, compositions, and uses of this compound
US7671094B2 (en) 2005-06-27 2010-03-02 Biovail Laboratories International S.R.L. Bupropion hydrobromide and therapeutic applications
TW200812993A (en) * 2006-05-02 2008-03-16 Lundbeck & Co As H New uses of escitalopram
US8318813B2 (en) * 2007-09-13 2012-11-27 Lcs Group, Llc Method of treating binge eating disorder
US20090246276A1 (en) * 2008-01-28 2009-10-01 Graham Jackson Pharmaceutical Compositions
AU2010252740A1 (en) * 2009-05-26 2012-01-12 Shire Llc Methods of enhancing selective serotonin reuptake inhibitor effects in mammals
WO2012028834A1 (en) * 2010-09-01 2012-03-08 Marcel Petrus Maria Bartels Use of bupropion in treating sexual dysfunction
US20140335139A1 (en) 2013-05-13 2014-11-13 NeuOra Microceuticals, LLC Long lasting breath mint
US20240122945A1 (en) * 2021-01-28 2024-04-18 Sage Therapeutics, Inc. Use of neuroactive steroids for treatment of sexual dysfunction

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE759838A (fr) 1969-12-04 1971-06-03 Wellcome Found Cetones a activite biologique
US3885046A (en) 1969-12-04 1975-05-20 Burroughs Wellcome Co Meta chloro or fluoro substituted alpha-T-butylaminopropionphenones in the treatment of depression
USRE33994E (en) 1983-08-16 1992-07-14 Burroughs Wellcome Co. Pharmaceutical delivery system
US4507323A (en) * 1984-07-25 1985-03-26 Burroughs Wellcome Co. Treatment of psychosexual dysfunctions
US4723958A (en) 1986-05-23 1988-02-09 Merck & Co., Inc. Pulsatile drug delivery system
GB8814057D0 (en) 1988-06-14 1988-07-20 Lundbeck & Co As H New enantiomers & their isolation
US5007790A (en) 1989-04-11 1991-04-16 Depomed Systems, Inc. Sustained-release oral drug dosage form
US5582837A (en) 1992-03-25 1996-12-10 Depomed, Inc. Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
US5260068A (en) 1992-05-04 1993-11-09 Anda Sr Pharmaceuticals Inc. Multiparticulate pulsatile drug delivery system
GB9217295D0 (en) 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
US5260069A (en) 1992-11-27 1993-11-09 Anda Sr Pharmaceuticals Inc. Pulsatile particles drug delivery system
US5541231A (en) 1993-07-30 1996-07-30 Glaxo Wellcome Inc. Stabilized Pharmaceutical
US5358970A (en) 1993-08-12 1994-10-25 Burroughs Wellcome Co. Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
GB9315856D0 (en) 1993-07-30 1993-09-15 Wellcome Found Stabilized pharmaceutical
MY113429A (en) 1995-02-28 2002-02-28 Univ Temple Controlled release tablet containing swellable polyethylene oxide
US5656294A (en) 1995-06-07 1997-08-12 Cibus Pharmaceutical, Inc. Colonic delivery of drugs
US5972389A (en) 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
US5840329A (en) 1997-05-15 1998-11-24 Bioadvances Llc Pulsatile drug delivery system
CA2290624C (en) 1997-06-06 2006-12-05 John W. Shell Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs
US6110973A (en) * 1998-01-29 2000-08-29 Sepracor Methods for treating obesity and weight gain using optically pure (-)-bupropion
US6372254B1 (en) 1998-04-02 2002-04-16 Impax Pharmaceuticals Inc. Press coated, pulsatile drug delivery system suitable for oral administration
US6096341A (en) 1998-10-30 2000-08-01 Pharma Pass Llc Delayed release tablet of bupropion hydrochloride
JP4613275B2 (ja) 1998-11-02 2011-01-12 エラン ファーマ インターナショナル，リミティド 多粒子改質放出組成物
US8545880B2 (en) 1999-02-26 2013-10-01 Andrx Pharmaceuticals, Llc Controlled release oral dosage form
US6342496B1 (en) 1999-03-01 2002-01-29 Sepracor Inc. Bupropion metabolites and methods of use
WO2000059481A1 (en) 1999-04-06 2000-10-12 Pharmaquest Ltd. PHARMACEUTICAL DOSAGE FORM FOR PULSATILE DELIVERY OF d-threo-METHYLPHENIDATE AND A SECOND CNS STIMULANT
AR021155A1 (es) 1999-07-08 2002-06-12 Lundbeck & Co As H Tratamiento de desordenes neuroticos
JP2003510266A (ja) 1999-09-28 2003-03-18 ハー・ルンドベック・アクチエゼルスカベット 溶融顆粒化された調合物及びこの調合物から製造された、放出が調節された投薬形
SK287140B6 (sk) 1999-10-25 2010-01-07 H. Lundbeck A/S Spôsob prípravy citalopramu a medziprodukt na jeho výrobu
US6627223B2 (en) 2000-02-11 2003-09-30 Eurand Pharmaceuticals Ltd. Timed pulsatile drug delivery systems
WO2002010169A1 (en) * 2000-07-31 2002-02-07 F. Hoffmann-La Roche Ag Piperazine derivatives
US6500457B1 (en) 2000-08-14 2002-12-31 Peirce Management, Llc Oral pharmaceutical dosage forms for pulsatile delivery of an antiarrhythmic agent
CA2445843A1 (en) 2001-05-01 2002-11-07 H. Lundbeck A/S The use of enantiomeric pure escitalopram
AR034612A1 (es) 2001-06-25 2004-03-03 Lundbeck & Co As H Proceso para la preparacion del citalopram racemico y/o del s- o r-citalopram mediante la separacion de una mezcla de r- y s-citalopram
AR034759A1 (es) 2001-07-13 2004-03-17 Lundbeck & Co As H Metodo para la preparacion de escitalopram
PT1522539E (pt) 2001-07-31 2007-03-30 Lundbeck & Co As H Composição cristalina contendo escitalopram
US20030124196A1 (en) 2001-08-22 2003-07-03 Susan Weinbach Pulsatile release compositions and methods for enhanced intestinal drug absorption
US7163696B2 (en) 2001-10-11 2007-01-16 Pfizer Inc. Pharmaceutical formulations
IS7239A (is) 2001-12-14 2004-04-29 H. Lundbeck A/S Aðferð til framleiðslu á essítalóprami
EP1499300B1 (en) 2002-04-29 2009-03-18 Supernus Pharmaceuticals, Inc. Pharmaceutical formulations with improved bioavailability
PT1578738E (pt) 2002-12-23 2008-04-11 Lundbeck & Co As H Bromidrato de escitalopram e um método para a sua preparação
DE60327948D1 (de) 2002-12-24 2009-07-23 Immunofrontier Inc Polynukleotidhaltige impfstoffe
US7687645B2 (en) 2003-03-21 2010-03-30 H. Lundbeck A/S Intermediates for the preparation of citalopram and escitalopram
US20050054688A1 (en) * 2003-08-08 2005-03-10 Pfizer Inc Selective serotonin reuptake inhibitors in the treatment of disease
US20050196453A1 (en) 2004-03-05 2005-09-08 H. Lundbeck A/S Crystalline composition containing escitalopram
BRPI0514060A (pt) * 2004-08-03 2008-05-27 Orexigen Therapeutics Inc combinação de bupropion e um segundo composto para acarretar a perda de peso

Also Published As

Publication number Publication date
EA200801081A1 (ru) 2008-10-30
IL190831A0 (en) 2008-12-29
US7569605B2 (en) 2009-08-04
WO2007053796A3 (en) 2007-11-29
US20090264522A1 (en) 2009-10-22
JP2009511606A (ja) 2009-03-19
BRPI0617382A2 (pt) 2017-07-11
EP1954257A2 (en) 2008-08-13
WO2007053796A2 (en) 2007-05-10
EP1954257A4 (en) 2009-05-20
AU2006308635A1 (en) 2007-05-10
CA2625835A1 (en) 2007-05-10
US20070203231A1 (en) 2007-08-30
KR20080080094A (ko) 2008-09-02

Similar Documents

Publication Publication Date Title
NO20082203L (no) Fremgangsmater for a behandle sentralnervesystemforstyrrelser med en lavdosekombinasjon av escitalopram og bupropion
BR112017015536A2 (pt) ?métodos de purificação de canabinoides, suas composições e kits?
NO20055907L (no) Fremgangsmate for behandling av en angstforstyrrelse
BR112015012789A2 (pt) composição que compreende um agente de controle biológico e um inseticida
NO20060242L (no) Kombinasjonen av en serotonin-reopptaksinhibitor og agomelatin
WO2022221440A8 (en) Influenza-coronavirus combination vaccines
CR9697A (es) Procesos para la preparacion de compuestos de 4-amino-2-(2,6-dioxopiperidina-3-il)isoindolina-1.3 dione.
NO20084490L (no) Nye forbindelser
ECSP088539A (es) MÉTODO DE UTILIZACIÓN DE b-HIDROXI-b-METILBUTIRATO
NO20072352L (no) Forbindelser og sammensetninger som inhibitorer av cannabinoidreceptor 1-aktivitet
NO20072035L (no) Memantin for behandling av adferdsforstyrrelser hos barn
NO20062003L (no) Fremgangsmate og forbindelser for behandling av immunoinflammatoriske forstyrrelser
NO20100077L (no) Behandling med alfa7-selektive ligander
NO20084374L (no) Imidazoltiazolforbindelser for behandling av sykdom
DE602005020498D1 (de) Verfahren zur herstellung einer l-aminosäure unter verwendung eines bakteriums der familie enterobacteriaceae mit abgeschwächter expression des yafa-gens
EA201101575A1 (ru) Лечение наследственной оптической (зрительной) нейропатии лебера и доминантной атрофии зрительного нерва токотриенол хинонами
NO20070391L (no) Jernsulfatbasert fosfatadsorbent
MX2010005047A (es) Inhibidores de aldh-2 en el tratamiento de enfermedades psiquiatricas.
BR112021020183A2 (pt) Terapias gênicas para distúrbios lisossomais
NO20082679L (no) Sammensetning og fremgangsmate for a behandle CNS lidelser
ATE417119T1 (de) Verfahren zur herstellung einer nichtaromatischen l-aminosäure unter verwendung eines bakteriums der familie enterobacteriaceae mit abgeschwächter expression des csra-gens
CL2013003307A1 (es) Agente que comprende ciazofamida o fenamidona; y su uso para tratar micosis en peces e invertebrados en todos sus estadios de desarrollo causada por hongos de los generos saprolegnia, achlya y aphanomyces (div.sol.n°1056-08).
DK2108366T3 (da) Idebenon til behandling af respiratorisk sygdom ved muskeldystrofi
NO20083034L (no) Farmasoytiske formuleringer av escitalopram med modifisert og pulserende frigivelse
MX2011011494A (es) Derivados de quinona 2,3-dimetoxi-5-metil-6-(10-hidroxidecil)-1,4- benzoquinona para el tratamiento de esclerosis multiple progresiva primaria.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application